CN101613325B - Process for producing 5-hydroxymethylthiazole - Google Patents
Process for producing 5-hydroxymethylthiazole Download PDFInfo
- Publication number
- CN101613325B CN101613325B CN2008100316085A CN200810031608A CN101613325B CN 101613325 B CN101613325 B CN 101613325B CN 2008100316085 A CN2008100316085 A CN 2008100316085A CN 200810031608 A CN200810031608 A CN 200810031608A CN 101613325 B CN101613325 B CN 101613325B
- Authority
- CN
- China
- Prior art keywords
- hydroxymethylthiazole
- chloro
- ethanol
- ether
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- WKBQQWDVVHGWDB-UHFFFAOYSA-N 1,3-thiazol-5-ylmethanol Chemical compound OCC1=CN=CS1 WKBQQWDVVHGWDB-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 53
- PEOOQVDIOJQJHW-UHFFFAOYSA-N (2-chloro-1,3-thiazol-5-yl)methanol Chemical compound OCC1=CN=C(Cl)S1 PEOOQVDIOJQJHW-UHFFFAOYSA-N 0.000 claims abstract description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 20
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 239000003513 alkali Substances 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 239000002904 solvent Substances 0.000 claims abstract description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 32
- 238000006243 chemical reaction Methods 0.000 claims description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 11
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 238000006298 dechlorination reaction Methods 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- 235000017550 sodium carbonate Nutrition 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 abstract description 9
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 abstract description 5
- 229960000311 ritonavir Drugs 0.000 abstract description 5
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 abstract description 5
- 238000006722 reduction reaction Methods 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- VRMUIVKEHJSADG-UHFFFAOYSA-N 2-chloro-5-(chloromethyl)-1,3-thiazole Chemical compound ClCC1=CN=C(Cl)S1 VRMUIVKEHJSADG-UHFFFAOYSA-N 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000004064 recycling Methods 0.000 abstract 1
- 238000006042 reductive dechlorination reaction Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 239000012044 organic layer Substances 0.000 description 17
- 238000005406 washing Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 238000009835 boiling Methods 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 238000004821 distillation Methods 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- 238000003810 ethyl acetate extraction Methods 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 230000002194 synthesizing effect Effects 0.000 description 10
- 238000010992 reflux Methods 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 7
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- TZEMBFLDHOUKNI-UHFFFAOYSA-N (2-amino-1,3-thiazol-5-yl)methanol Chemical compound NC1=NC=C(CO)S1 TZEMBFLDHOUKNI-UHFFFAOYSA-N 0.000 description 2
- 229940124321 AIDS medicine Drugs 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 238000006193 diazotization reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- DWXKSCKBUSAOKS-UHFFFAOYSA-N ethyl 2-chloro-3-oxopropanoate Chemical compound CCOC(=O)C(Cl)C=O DWXKSCKBUSAOKS-UHFFFAOYSA-N 0.000 description 2
- CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical compound NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- DWNJWSPPORNJGV-UHFFFAOYSA-N (2-bromo-1,3-thiazol-5-yl)methanol Chemical class OCC1=CN=C(Br)S1 DWNJWSPPORNJGV-UHFFFAOYSA-N 0.000 description 1
- OSFYRJIHPBMDPW-UHFFFAOYSA-N 1,1,1,3-tetramethoxypropane Chemical compound COCCC(OC)(OC)OC OSFYRJIHPBMDPW-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- HZKMBJCDAXLMDN-UHFFFAOYSA-N 2-amino-1,3-thiazole-5-carbaldehyde Chemical compound NC1=NC=C(C=O)S1 HZKMBJCDAXLMDN-UHFFFAOYSA-N 0.000 description 1
- DJUWIZUEHXRECB-UHFFFAOYSA-N 2-bromo-1,3-thiazole-5-carbaldehyde Chemical class BrC1=NC=C(C=O)S1 DJUWIZUEHXRECB-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 229940122440 HIV protease inhibitor Drugs 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- -1 carboxylate salt Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100316085A CN101613325B (en) | 2008-06-27 | 2008-06-27 | Process for producing 5-hydroxymethylthiazole |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100316085A CN101613325B (en) | 2008-06-27 | 2008-06-27 | Process for producing 5-hydroxymethylthiazole |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101613325A CN101613325A (en) | 2009-12-30 |
CN101613325B true CN101613325B (en) | 2011-09-14 |
Family
ID=41493232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100316085A Expired - Fee Related CN101613325B (en) | 2008-06-27 | 2008-06-27 | Process for producing 5-hydroxymethylthiazole |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101613325B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111548321A (en) * | 2020-04-13 | 2020-08-18 | 南通森萱药业有限公司 | Synthetic method of ritonavir intermediate 5-hydroxymethylthiazole |
CN112546969B (en) * | 2020-12-07 | 2022-12-23 | 安徽贝克制药股份有限公司 | Catalytic hydrogenation continuous production device and preparation method of ritonavir intermediate |
-
2008
- 2008-06-27 CN CN2008100316085A patent/CN101613325B/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101613325A (en) | 2009-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3278649B2 (en) | Method for producing benzothiophene derivative | |
CN105820126B (en) | A kind of preparation method of olaparib | |
CN1042328C (en) | Substituted cyclohexane derivative, preparation and application in illness treatment of same | |
CN100384801C (en) | (E)-3,5-dimethox-4'-hydroxy diphenyl ethylene synthesis method | |
CN101613325B (en) | Process for producing 5-hydroxymethylthiazole | |
JP2007536358A (en) | Synthesis of antidiabetic rosiglitazone derivatives | |
EP3444244B1 (en) | Preparation process for high-purity dabigatran etexilate | |
CN103497097A (en) | Substituted fluorenone and preparation method thereof | |
CN105646285B (en) | One kind dimension Lactel sieve intermediate and its preparation method and application | |
CN1106391C (en) | Magnolol series of compounds, synthesizing process thereof, and medicinal composition using same as active component | |
CN1047289A (en) | (sulfo-) morpholinyl of rhinovirus and the preparation method of piperazinyl alkylphenol ethers | |
CN103951588B (en) | A kind of method synthesizing onglyza intermediate N-tertbutyloxycarbonyl-3-hydroxyl-1-adamantyl-D-glycine | |
CN101798297B (en) | Chemical synthesis method of laetispicine | |
JP2005500379A (en) | Oxime derivatives to treat dyslipidemia and hypercholesterolemia | |
CN103467445A (en) | Preparation method of alogliptin benzoate | |
JPH0699398B2 (en) | Substituted 1- [3- (heteroarylmethoxy) phenylalkanols and related compounds in the treatment of asthma, arthritis and related diseases | |
CN101538253A (en) | Method for preparing repaglinide intermediate | |
CN109081827A (en) | A kind of preparation method and application of bilastine | |
CN110423228B (en) | Method for preparing darunavir intermediate | |
WO2009148195A1 (en) | 5-(4-hydroxybenzyl)thiazolidine-2,4-dione as intermediate for synthesis of thiazolidinedione based compounds and process for preparing the same | |
CN104876806A (en) | Novel method for synthesizing bisoprolol importance intermediate | |
CN107936078A (en) | A kind of new method for preparing shellfish cholic acid difficult to understand | |
CN102690211A (en) | Method for preparing tolvaptan intermediate | |
CN104276979B (en) | The preparation method of agomelatine intermediate body | |
CN102203069A (en) | Process for the preparation of substituted phenylalanines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CENTRAL SOUTH UNIVERSITY OF FORESTRY AND TECHNOLOG Free format text: FORMER OWNER: YE CUICENG Effective date: 20111031 Free format text: FORMER OWNER: XIAO HONGBO KUANG CHUNTAO YIN ZUOHU SUN HANZHOU |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20111031 Address after: 410004 Shaoshan South Road, Hunan, No. 498, No. Patentee after: Central South University of Forestry and Technology Address before: 410004 Institute of Applied Chemistry, Central South University of Forestry and Technology, Hunan, Changsha Co-patentee before: Xiao Hongbo Patentee before: Ye Cuiceng Co-patentee before: Kuang Chuntao Co-patentee before: Yin Zuohu Co-patentee before: Sun Hanzhou |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110914 Termination date: 20120627 |